BEYOND AIR INC. - COMMON STOCK

Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

11 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

29 Oct 2024 13:22:08 By Nasdaq GlobeNewswire

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

07 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

02 Oct 2024 04:30:00 By Nasdaq GlobeNewswire

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

27 Sep 2024 04:34:00 By Nasdaq GlobeNewswire

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

27 Sep 2024 04:32:00 By Nasdaq GlobeNewswire

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

27 Sep 2024 04:30:00 By Nasdaq GlobeNewswire

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

23 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

06 Aug 2024 13:05:01 By Nasdaq GlobeNewswire

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

31 Jul 2024 13:15:00 By Nasdaq GlobeNewswire

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

23 Jul 2024 13:05:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

16 Jul 2024 13:05:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

24 Jun 2024 13:15:00 By Nasdaq GlobeNewswire

Beyond Air® Appoints David Webster as Chief Commercial Officer

13 Jun 2024 13:05:00 By Nasdaq GlobeNewswire

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

03 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

23 May 2024 13:09:12 By Nasdaq GlobeNewswire

Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting

01 May 2024 04:00:00 By Nasdaq GlobeNewswire

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

20 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

12 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

18 Jan 2024 05:00:00 By Nasdaq GlobeNewswire